Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Investing Activities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Cash from Investing Activities for 11 consecutive years, with $39.6 million as the latest value for Q3 2025.

  • Quarterly Cash from Investing Activities fell 52.88% to $39.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $169.6 million through Sep 2025, down 12.61% year-over-year, with the annual reading at $162.1 million for FY2024, 4445.91% up from the prior year.
  • Cash from Investing Activities for Q3 2025 was $39.6 million at Editas Medicine, down from $42.6 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $89.2 million in Q3 2022, with the low at -$102.8 million in Q3 2023.
  • Average Cash from Investing Activities over 5 years is $18.8 million, with a median of $23.3 million recorded in 2023.
  • The sharpest move saw Cash from Investing Activities soared 1637.7% in 2022, then crashed 215.23% in 2023.
  • Over 5 years, Cash from Investing Activities stood at -$22.8 million in 2021, then dropped by 20.53% to -$27.5 million in 2022, then soared by 328.28% to $62.8 million in 2023, then tumbled by 50.74% to $31.0 million in 2024, then increased by 27.83% to $39.6 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at $39.6 million, $42.6 million, and $56.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.